Nvidia (NVDA), the Silicon Valley-based microprocessing giant, has seen its shares climb 24% since the start of the year, closing at $594.91 on January 21, 2024. The company has been making strides in the life sciences industry, particularly in the field of artificial intelligence (AI).
Recursion Collaboration
Nvidia has invested $50 million in Recursion, a San Francisco-based AI-focused drug developer, and the two companies have launched a collaboration. Recursion uses AI to identify new drug candidates and has developed a platform that can screen thousands of compounds in a matter of days. Nvidia’s technology is being used to accelerate the drug discovery process by providing Recursion with access to its high-performance computing resources.
Amgen Partnership
Nvidia has also partnered with Amgen, a biotechnology company, to develop AI tools for drug discovery. The two companies are working together to develop a generative AI cloud-based platform called BioNeMo™, which is designed to enable faster discovery and design of drugs.
Market Response
Nvidia’s shares have more than tripled in price during 2023, starting with a 180% jump in the first half of the year that grew to 246% as shares zoomed from $143. Its surge this year comes on top of its previous successes in AI and the broader promise of the technology to reshape biopharma.
What is the future of Nvidia’s partnership with Amgen?
Nvidia’s partnership with Amgen is expected to continue to advance drug discovery using AI models. Amgen plans to create AI models trained to analyze one of the world’s largest human datasets, which will enable the company to explore and develop therapeutic proteins for the next generation of medicine. Amgen has also been accessing Nvidia’s BioNeMo via Nvidia DGX Cloud, an AI supercomputing service, to build generative AI models to accelerate drug discovery.
The two companies are working together to develop a generative AI cloud-based platform called BioNeMo, which is designed to enable faster discovery and design of drugs. The platform is now in beta, featuring fresh foundational models and introducing a new hosted model by Recursion specifically. The partnership is expected to accelerate the development of AI-driven precision medicine models, leading to individualized therapies for patients with serious diseases.
What are the goals of the expanded collaboration initiative between Nvidia and Amgen?
The expanded collaboration initiative between Nvidia and Amgen aims to advance drug discovery using AI models. The goals of the collaboration include:
Developing AI models: Amgen plans to create AI models trained to analyze one of the world’s largest human datasets, which will enable the company to explore and develop therapeutic proteins for the next generation of medicine.
- Accelerating drug discovery: By adopting Nvidia’s BioNeMo, Amgen researchers can build generative AI models to accelerate drug discovery, helping develop more effective drugs and avoiding unwanted effects like immune responses.
- Individualized therapies: The collaboration is expected to accelerate the development of AI-driven precision medicine models, leading to individualized therapies for patients with serious diseases.
- Advancing cell morphology studies: Its partnership with Deepcell focuses on advancing cell morphology studies with generative AI, which will help in the development of new therapeutic approaches.
- Leveraging Nvidia’s computing expertise: Amgen will use Nvidia’s drug discovery generative AI platform BioNeMo Cloud service to accelerate drug discovery and development
Conclusion
In conclusion, Nvidia’s collaborations with Recursion and Amgen have been driving the company’s success in the life sciences industry, particularly in the field of AI. The company’s shares have climbed 24% since the start of the year, and its success is expected to continue as it continues to make strides in AI and drug discovery.
Related article:
